SceneRay Medical participated in the 3rd Oriental Deep Brain Stimulation Think Tank Conference, sharing new breakthroughs in DBS applications and looking forward to the future of DBS technology.

From November 3 to 5, 2023, the 3rd Eastern Deep Brain Stimulation Think Tank Conference was successfully held in Singapore. The conference was co-organized and supported by Fudan University's Institute of Brain-Inspired Intelligence Science and Technology, Beijing Tiantan Hospital affiliated with Capital Medical University, West China Hospital affiliated with Sichuan University, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, the National University of Singapore, the Queensland Brain Institute, and the University of Cambridge. The conference brought together renowned experts in neurology, neurosurgery, psychiatry, electrophysiology, and robotics from both China and abroad to discuss the latest advances and future trends in DBS technology for the treatment of neurological and psychiatric disorders.

SceneRay Medical was invited to attend the conference and fully supported its organization. Jingyu Medical hopes to provide better treatment options for patients with neurological and psychiatric diseases through technological innovation.

At the conference, Dr. Chen Lei, a clinical expert at SceneRay Medical, shared the company's latest research and practical achievements in the treatment of drug addiction and refractory obsessive-compulsive disorder. The experts at the conference highly praised SceneRay Medical's achievements and engaged in in-depth discussions on the future development of DBS technology in the treatment of neurological and psychiatric disorders. They all agreed that SceneRay Medical's outstanding contributions to brain science will bring new treatment options to patients with mental illness and help them improve their lives.

Deep brain stimulation (DBS) is a therapeutic approach that uses electrodes implanted in the brain to regulate nerves. This technology has achieved significant results in treating movement disorders such as Parkinson's disease and dystonia, and is widely used worldwide.

As an innovative company in the field of brain science, SceneRay Medical has been committed to promoting new applications and developments in DBS technology in recent years. SceneRay Medical's Chief Engineer, Zhu Weiran, gave a detailed report on "SceneRay DBS Product and Technology Development," explaining SceneRay corporate vision: to create more accurate and reliable treatment plans and products for patients with brain functional diseases, and to provide more diverse treatment options for functional neurosurgery and psychiatric disease treatment research.

It is precisely because of this unwavering commitment to its original aspirations that Jingyu Medical's "Dual-Target Combined Stimulation" DBS system for post-abstinence opioid addiction relapse prevention has received Breakthrough Device Designation from the US FDA. Furthermore,SceneRay Medical is actively advancing research into DBS treatment for refractory obsessive-compulsive disorder (OCD). It pioneered a dual-target DBS treatment approach and developed a brain-computer interface dual-target brain pacemaker, bringing hope to patients with refractory OCD.

At the conference, industry experts from home and abroad engaged in in-depth discussions on the clinical applications of DBS in neurological and psychiatric disorders. Professor Sun Bomin of the Department of Functional Neurosurgery at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, discussed DBS treatment of the habenula and bed nucleus of the stria terminalis. Professor Wang Wei of the Department of Functional Neurosurgery at West China Hospital, affiliated with Sichuan University, shared insights into the neurophysiological mechanisms of OCD and demonstrated the clinical efficacy of dual-target DBS in treating refractory OCD. These discussions sparked a cross-fertilization of ideas and promoted the further development of DBS technology in the treatment of neurological and psychiatric disorders.

As a key innovation entity in the field of brain science, SceneRay Medical will continue to work hard to develop more accurate and reliable treatment plans and products for brain functional diseases, promote industry development, and reshape patients' healthy lives!